Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors :: Benson AB 3rd
Venook AP
Cederquist L
Chan E
Chen YJ
Cooper HS
Deming D
Engstrom PF
Enzinger PC
Fichera A
Grem JL
Grothey A
Hochster HS
Hoffe S
Hunt S
Kamel A
Kirilcuk N
Krishnamurthi S
Messersmith WA
Mulcahy MF
Murphy JD
Nurkin S
Saltz L
Sharma S
Shibata D
Skibber JM
Sofocleous CT
Stoffel EM
Stotsky-Himelfarb E
Willett CG
Wu CS
Gregory KM
Freedman-Cass D
Source :: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2017 Mar; Vol. 15 (3), pp. 370-398.
Publication Year :: 2017
Abstract: This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.<br /> (Copyright © 2017 by the National Comprehensive Cancer Network.)